China's National Healthcare Security Administration recently concluded a consultation for the second batch of 28 drugs intended for reference in the 2026 medical insurance catalog. Experts from various medical and economic fields reviewed the submitted information. The results of this consultation have been communicated to the applicant companies, with further review processes outlined for drugs that may be included in the 2026 catalog adjustments. AI
RANK_REASON The cluster discusses a policy and consultation process related to drug inclusion in a national medical insurance catalog, which falls under research and policy. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →